| 000 | 01730 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513134715.0 | ||
| 264 | 0 | _c19980302 | |
| 008 | 199803s 0 0 eng d | ||
| 022 | _a0732-183X | ||
| 024 | 7 |
_a10.1200/JCO.1998.16.2.771 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNolte, M J | |
| 245 | 0 | 0 |
_aAssuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cFeb 1998 |
||
| 300 |
_a771-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntiemetics _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aDexamethasone _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Utilization |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGranisetron _xtherapeutic use |
| 650 | 0 | 4 | _aGuideline Adherence |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNausea _xchemically induced |
| 650 | 0 | 4 |
_aOndansetron _xtherapeutic use |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 | _aQuality Assurance, Health Care |
| 650 | 0 | 4 |
_aSerotonin Antagonists _xtherapeutic use |
| 650 | 0 | 4 |
_aVomiting _xchemically induced |
| 700 | 1 | _aBerkery, R | |
| 700 | 1 | _aPizzo, B | |
| 700 | 1 | _aBaltzer, L | |
| 700 | 1 | _aGrossano, D | |
| 700 | 1 | _aLucarelli, C D | |
| 700 | 1 | _aKris, M G | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 16 _gno. 2 _gp. 771-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.1998.16.2.771 _zAvailable from publisher's website |
| 999 |
_c9438320 _d9438320 |
||